Janney Montgomery Scott LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 783,946 shares of the company’s stock after buying an additional 12,078 shares during the period. Johnson & Johnson comprises about 1.2% of Janney Montgomery Scott LLC’s portfolio, making the stock its 7th largest position. Janney Montgomery Scott LLC’s holdings in Johnson & Johnson were worth $101,921,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Harding Loevner LP bought a new position in Johnson & Johnson during the 2nd quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares in the last quarter. IHT Wealth Management LLC grew its holdings in Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after acquiring an additional 3,467 shares in the last quarter. Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $124,000. Finally, Shine Investment Advisory Services Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $177,000. Institutional investors own 67.35% of the company’s stock.
In related news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.19% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion during the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. Johnson & Johnson’s revenue was up 11.5% on a year-over-year basis. During the same period last year, the firm posted $1.58 EPS. research analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th were given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.50%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s payout ratio is currently 61.88%.
A number of analysts have recently weighed in on JNJ shares. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price target on the stock in a report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Finally, Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $146.26.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.